Hypertensive Disorders of Pregnancy (Part 2): Preconception Counseling, Lactation Pharmacology, and Lifelong Cardiometabolic Risk

Key Takeaways

• The clinical consequences of hypertensive disorders of pregnancy extend far beyond delivery. Preeclampsia and gestational hypertension identify women at persistently elevated risk of chronic hypertension, ischemic heart disease, heart failure, stroke, and chronic kidney disease. Yet, the vast majority of affected women transition out of obstetric care without a structured cardiovascular follow-up plan.
• Mechanistically, placental ischemia triggers the release of soluble fms-like tyrosine kinase 1 (sFlt-1)—which binds and neutralizes VEGF and placental growth factor (PlGF)—and soluble endoglin, which disrupts endothelial TGF-beta signaling, leading to maternal endothelial and glomerular podocyte injury. Maternal metabolic predisposition and vascular reserve, including obesity and hyperleptinemia, play critical priming roles in converting placental dysfunction into clinically overt preeclampsia. Vascular and renal damage may persist well beyond this antiangiogenic surge.
• Preconception care must address several critical priorities. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers should be discontinued and switched prior to or at conception, and statins should be stopped. Screening for primary aldosteronism must be performed before pregnancy because pregnancy itself disrupts the aldosterone-to-renin ratio. Low-dose aspirin initiation should be planned between 12 and 16 weeks of gestation, and adequate calcium supplementation must be ensured in women with low dietary calcium intake.
• In the postpartum period, blood pressure typically peaks between days 3 and 6. Blood pressure must be measured within the first 72 hours following delivery and again at days 7 to 10. Persistent values of 150/100 mmHg or higher should be treated, and severe elevations of 160/110 mmHg or higher warrant urgent intervention. Persistence of hypertension beyond 12 weeks defines chronic hypertension and necessitates an evaluation for secondary causes.
• During lactation, extended-release nifedipine, labetalol, and enalapril are reasonable first-line options, with metoprolol and amlodipine serving as alternative agents. Atenolol should be avoided, and methyldopa should be discontinued postpartum due to the risk of depression. Neonates exposed to beta-blockers must be monitored for hypoglycemia and bradycardia. Maternal creatinine and potassium levels should be checked within two weeks of initiating an ACE inhibitor.

Introduction and Clinical Background

Hypertensive disorders of pregnancy were traditionally viewed as self-limited conditions that resolve with delivery of the placenta. Today, this paradigm is no longer tenable. Chronic hypertension, gestational hypertension, preeclampsia with or without severe features, and preeclampsia superimposed on chronic hypertension each delineate cohorts of women whose cardiovascular and renal trajectories diverge sharply from those of their normotensive peers. Pregnancy functions as a physiological stress test, and failing this test carries prognostic weight that reverberates across decades.

The epidemiological landscape is worsening. Rising pre-pregnancy hypertension prevalence and persistent racial and ethnic disparities in preeclampsia represent foremost concerns in cardiovascular medicine^[1]. Recent rates of pre-pregnancy hypertension and diabetes have also been characterized in detail across a multiethnic cohort of pregnant individuals in a demographically diverse US state^[2]. These data underscore that an increasing proportion of pregnancies begin against a backdrop of established cardiometabolic disease. The drivers of this secular trend are well recognized: advanced maternal age at first birth, escalating obesity prevalence, younger onset of type 2 diabetes, and the expanding use of assisted reproductive technology in older women.

In clinical practice, three critical windows of opportunity are repeatedly missed. The first is the preconception visit, the optimal setting in which teratogenic or fetotoxic antihypertensive regimens can be safely switched prior to conception, secondary causes of hypertension can be investigated, and preventive aspirin prophylaxis can be proactively planned. The second is the early postpartum period, when blood pressure frequently surges following hospital discharge while clinical surveillance remains inadequate. The third is the transition from obstetric care to primary care or cardiovascular follow-up, where a history of preeclampsia should be documented as an independent cardiovascular risk-enhancing factor, yet is frequently lost from the medical record entirely.

This second part of the review addresses each of these windows in sequence. It examines the mechanisms linking placental pathology to lasting maternal vascular injury, reviews the evidence and guideline consensus governing management across the preconception, postpartum, and lactation periods, and provides a practical bedside algorithm for dosing, monitoring, and long-term surveillance.

Molecular and Pathophysiological Mechanisms

Placental Antiangiogenic Imbalance and Maternal Endothelium

The canonical model of early-onset preeclampsia begins with impaired extravillous trophoblast invasion and incomplete remodeling of the uterine spiral arteries. This culminates in a high-resistance, pulsatile uteroplacental circulation accompanied by ischemia-reperfusion injury and oxidative stress within the syncytiotrophoblast. The stressed placenta secretes soluble fms-like tyrosine kinase 1 (sFlt-1), a splice variant of vascular endothelial growth factor receptor 1. sFlt-1 binds to and neutralizes vascular endothelial growth factor and placental growth factor (PlGF). Concurrently, soluble endoglin antagonizes transforming growth factor-beta signaling on the endothelial surface.

The downstream consequences of this cascade are systemic. Endothelial nitric oxide synthase activity and prostacyclin production decrease, while endothelin-1 and thromboxane levels rise. Vascular sensitivity to angiotensin II is heightened; this hyperresponsiveness is further exacerbated in some women by agonistic autoantibodies directed against the angiotensin II type 1 receptor. Because the maintenance of the fenestrated glomerular endothelium depends on podocyte-derived vascular endothelial growth factor, the glomerulus is particularly vulnerable to this process. The resulting lesion of glomerular endotheliosis forms the basis of proteinuria and is accompanied by the shedding of podocytes into the urine (podocyturia).

Maternal Susceptibility: Metabolic and Adipokine Signaling

Placental dysfunction alone does not dictate the maternal phenotype. In a 24-year cohort encompassing more than 90,000 births, investigators classified 2,060 cases of Doppler-defined placental fetal growth restriction. Only 529 (25.7%) of these cases were accompanied by preeclampsia; the vast majority presented as vascular fetal growth restriction without preeclampsia. Preeclampsia-associated growth restriction was correlated with chronic hypertension (odds ratio 2.8 to 3.0), prior preeclampsia (odds ratio 3.3 to 9.9 in multiparas), renal disease (odds ratio 5.0 to 7.8), and obesity (odds ratio 1.4 to 2.1), whereas smoking exhibited a protective correlation (attributable to carbon monoxide-mediated suppression of antiangiogenic factors), a well-recognized epidemiological paradox in the literature^[3]. These findings demonstrate that preexisting maternal vascular, renal, and metabolic reserve serves as the principal threshold governing whether clinical hypertensive disease will be triggered in the presence of a dysfunctional placenta, thereby representing a rational target for preconception interventions.

Adipokine signaling provides a plausible mechanistic bridge in this process. Among 1,504 women in the Project Viva cohort, preeclampsia developed in 0.4% of women in the lowest tertile of mid-pregnancy leptin levels, 4.0% in the middle tertile, and 5.8% in the highest tertile. Adjusted odds ratios—independent of prepregnancy body mass index, early gestational weight gain, history of hypertension, age, and parity—were calculated as 7.5 (95% CI 1.7 to 32.7) for the middle tertile and 7.0 (95% CI 1.5 to 31.9) for the highest tertile. An odds ratio signal of 6.4 was also observed for the development of self-reported preeclampsia in subsequent pregnancies, although the confidence interval of 0.7 to 57.0 was too wide to draw a definitive clinical conclusion^[4]. Leptin activates sympathetic outflow via hypothalamic melanocortin pathways, induces endothelial dysfunction, and is also secreted by the hypoxic placenta itself. Consequently, whether hyperleptinemia is a cause or a marker of placental stress remains to be elucidated.

Persistent Postpartum Cardiovascular and Renal Injury

Circulating sFlt-1 declines within a few days postpartum; however, the vascular footprint it leaves behind is not erased. Two non-mutually exclusive hypotheses explain this long-term increase in risk. The shared-risk hypothesis posits that preeclampsia unmasks preexisting endothelial dysfunction, insulin resistance, and an adverse lipid profile that would have emerged later in the woman’s life regardless. The injury hypothesis suggests that the antiangiogenic insult induces permanent damage. Potential lesions include residual endothelial dysfunction, concentric left ventricular remodeling with diastolic dysfunction, arterial stiffening, and permanent podocyte loss. Because podocytes are terminally differentiated cells with highly limited regenerative capacity, an episode of preeclampsia can deplete the nephron reserve, predisposing the patient to future albuminuria and eGFR decline when secondary insults (second hits)—such as obesity, diabetes, or recurrent preeclampsia—accumulate.

Lactational Pharmacokinetics and the Neonatal RAAS

The transfer of drugs into breast milk follows predictable physicochemical rules. Low maternal protein binding, high lipid solubility, low molecular weight, and weak basic properties facilitate transfer into milk. Weak bases undergo ion trapping in breast milk, which is slightly more acidic than plasma. The relative infant dose, which represents the weight-adjusted infant intake expressed as a percentage of the maternal dose, is conventionally considered reassuring when below 10%. Preferred agents in clinical practice, such as nifedipine, labetalol, propranolol, enalapril, and captopril, yield very low relative infant doses through mechanisms including high protein binding, limited milk transfer, or poor neonatal oral bioavailability. Conversely, atenolol, which has low protein binding and is eliminated renally, accumulates in both breast milk and the neonate.

The renin-angiotensin-aldosterone system (RAAS) warrants special consideration in this context. In the fetus, glomerular filtration depends on angiotensin II-mediated efferent arteriolar tone. For this reason, exposure to ACE inhibitors or angiotensin receptor blockers during the second and third trimesters leads to renal tubular dysgenesis, oligohydramnios, pulmonary hypoplasia, and calvarial hypoplasia. Following delivery, the kidney of a term infant remains relatively RAAS-dependent for several weeks, and that of a preterm infant for an even longer duration. This pathophysiology underpins the preference for ACE inhibitors with well-characterized pharmacokinetic profiles and low milk transfer in breastfeeding mothers of term infants, as well as the far more cautious approach mandated in preterm infants.

Clinical Evidence and Guideline Comparisons

Preconception Cardiovascular Health and Placental Outcomes

The premise that preconception maternal cardiovascular status shapes pregnancy outcomes has moved beyond mere inference to become the direct subject of clinical investigation. The relationship between preconception maternal cardiovascular health and obstetric complications attributed to uteroplacental insufficiency has been specifically examined^[5]. The growth restriction cohort described above complements this line of research: it identifies chronic hypertension, renal disease, and elevated body mass index as key risk factors that markedly increase the likelihood of developing preeclampsia against a backdrop of placental insufficiency. Considered together, these observations justify viewing the preconception visit not merely as an obstetric formality, but directly as a critical window for cardiovascular intervention.

Preventive Interventions Before and in Early Pregnancy

Micronutrient supplementation has been evaluated in high-risk women. A systematic review and meta-analysis identified 20 randomized trials testing vitamins C and E, calcium, vitamin D, folic acid, magnesium, and multiple micronutrients. A history of preeclampsia was the most commonly used criterion to define high risk, and no trial utilized a validated prediction model. Calcium supplementation was associated with a risk difference of −0.15 (95% CI −0.27 to −0.03); however, substantial heterogeneity was observed (I² = 83.4%). Vitamin D was associated with a risk difference of −0.09 (95% CI −0.17 to −0.02); however, substantial heterogeneity was observed, with substantial heterogeneity (I² = 83.4%). Vitamin D was associated with a risk difference of −0.09 (95% CI −0.17 to −0.02), with no measurable heterogeneity detected^[6]. The authors emphasized small sample sizes and methodological variability. In particular, the calcium estimate should not be interpreted as a 15-percentage-point benefit generalizable to well-nourished populations, as this effect is thought to be concentrated primarily among women with low baseline calcium intake.

Low-dose aspirin remains the sole pharmacological prophylactic modality supported by robust randomized evidence; nevertheless, clinical implementation remains the weak link. A nationwide analysis evaluated aspirin use for preeclampsia prophylaxis among pregnant women with pregestational diabetes, obesity, chronic hypertension, and combinations of these conditions^[7]. The study findings reveal that even in the very high-risk cardiometabolic phenotypes where aspirin is most clearly indicated, it remains markedly underprescribed in clinical practice, highlighting a substantial gap between guideline recommendations and real-world care.

Postpartum Hypertension and the Follow-up Gap

Hypertension may persist from pregnancy or develop de novo after delivery. The fact that many women present after hospital discharge and slip through the cracks as medical surveillance wanes multiplies these risks; furthermore, the scarcity of standard guidelines specific to this period has fostered considerable diagnostic and therapeutic heterogeneity in clinical practice^[8]. Physiology dictates this timing. Mobilization of extracellular fluid, withdrawal of pregnancy-associated vasodilators, residual antiangiogenic activity, and the frequent use of nonsteroidal anti-inflammatory analgesics converge between postpartum days 3 and 6, when many women have already returned home. A significant proportion of postpartum eclampsia and stroke cases occur after discharge, underscoring the rationale for early postpartum blood pressure checks and home monitoring programs utilizing validated remote-tracking devices.

Comparison of Guideline Approaches

Multiple national guideline documents address the management of hypertensive disorders of pregnancy, including the UK NICE guidance^[9] and the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) guidelines^[10]. Both texts have been revised over time. Current iterations of these guidelines, alongside those from the American College of Obstetricians and Gynecologists (ACOG), the International Society for the Study of Hypertension in Pregnancy (ISSHP), and the European Society of Cardiology, converge on several fundamental principles. Antihypertensive therapy is indicated for persistent blood pressure values of 140/90 mmHg or higher in most pregnant women with chronic hypertension. ACOG transitioned to this threshold in 2022, whereas NICE and ISSHP recommend a target of approximately 135/85 mmHg. Severe hypertension, defined as 160/110 mmHg or higher, mandates treatment within 30 to 60 minutes.

Guidelines diverge regarding preferred agents, aspirin dosing, and postpartum thresholds. While NICE favors labetalol as first-line therapy, followed by nifedipine and then methyldopa, ACOG considers labetalol and nifedipine equivalent. For aspirin, NICE recommends 75 to 150 mg daily, whereas ACOG and the US Preventive Services Task Force specify 81 mg, and ISSHP and FIGO prefer an evening dose of approximately 150 mg. Although guidelines recommend initiating aspirin ideally before 16 weeks of gestation (ACOG notes it may be started between 12 and 28 weeks in appropriate risk groups), there is consensus that treatment should be continued until 36 weeks or until delivery. In the postpartum period, NICE recommends initiating treatment when blood pressure reaches 150/100 mmHg or higher, identifying enalapril as the preferred agent in breastfeeding women.

RAAS inhibitors remain the area of greatest ongoing uncertainty. In response to a review calling for clearer recommendations on the use of these agents in women of childbearing potential, during pregnancy, and during lactation, the British and Irish Hypertension Society outlined key prescribing challenges and identified areas requiring further research^[11]. The central dilemma stems from the fact that ACE inhibitors represent first-line therapy for many reproductive-aged women with chronic hypertension or diabetic kidney disease. This creates a large exposed population in whom lactation-specific data have been reviewed for both ACE inhibitors and angiotensin receptor blockers^[12]. While data are reassuring for enalapril and captopril, evidence remains sparse for angiotensin receptor blockers.

Long-Term Cardiovascular and Renal Evidence

Large-scale population registries and meta-analyses have consistently linked preeclampsia and gestational hypertension to future chronic hypertension, coronary artery disease, heart failure, stroke, vascular dementia, and end-stage renal disease. The risk gradient is steepest following early-onset or recurrent preeclampsia, and after presentations complicated by preterm birth or growth restriction. The exact magnitude of this long-term risk elevation varies across cohorts depending on the population studied, duration of follow-up, and statistical adjustment models. Clinicians should therefore consider the cumulative cardiometabolic burden of the presentation rather than relying on a single static risk coefficient, as estimates differ according to population, duration of follow-up, and adjustment strategies. What remains uncontested is the clinical implication: the 2019 ACC/AHA primary prevention guideline lists preeclampsia and premature menopause among risk-enhancing factors, and European prevention guidelines similarly recommend periodic screening for hypertension and metabolic disease following a hypertensive pregnancy.

Practical Implications and Safety Profile

Preconception Counseling and Medication Transition

Every woman of reproductive potential receiving antihypertensive therapy should have a documented contraception and pregnancy plan. The preconception evaluation should establish baseline parameters for comparison during subsequent follow-up: serum creatinine and eGFR, urine albumin-to-creatinine or protein-to-creatinine ratio, electrolytes, liver enzymes, platelet count, uric acid, fasting glucose or HbA1c, and a lipid profile. An ECG should be obtained; echocardiography should be performed in the presence of longstanding or poorly controlled hypertension or suspected target-organ damage.

ACE inhibitors and angiotensin receptor blockers (ARBs) must be transitioned to safe alternatives prior to conception. Angiotensin receptor blockers must always be discontinued in advance as soon as pregnancy is planned. In select cases with marked proteinuria or advanced diabetic kidney disease who derive critical renoprotective benefit from RAAS blockade, ACE inhibitors alone may exceptionally be continued until conception, with strict instructions to the patient to perform rigorous home pregnancy testing and discontinue the drug immediately on the day of a positive result. Whether first-trimester exposure is truly teratogenic remains debated, as signals in observational data are confounded by maternal hypertension and diabetes. In contrast, the fetotoxicity of second- and third-trimester exposure is well established. Similar caution applies to direct renin inhibitors, angiotensin receptor-neprilysin inhibitors, and mineralocorticoid receptor antagonists. Spironolactone carries antiandrogenic potential for the male fetus; eplerenone has been used only anecdotally during pregnancy. Statins should be discontinued. Previously initiated thiazide therapy may be continued in select women; however, many clinicians prefer to switch agents to avoid plasma volume contraction.

Replacement agents include extended-release nifedipine, initiated at 30 mg once daily and titrated to 60 to 90 mg and up to a maximum of 120 mg daily, or labetalol, initiated at 100 to 200 mg twice daily and titrated to a typical maximum of 2,400 mg daily in two to three divided doses. When these agents are not tolerated, methyldopa at 250 mg two to three times daily is an alternative. Weight optimization, daily folic acid 0.4 mg (higher doses in selected high-risk groups according to local guidelines), and an interpregnancy interval of at least 18 months complete the counseling. Aspirin at guideline-recommended doses should be planned starting at 12 to 16 weeks. In populations with low dietary calcium intake, elemental calcium supplementation of 1.5 to 2.0 g daily in divided doses should be provided in accordance with World Health Organization (WHO) guidelines.

Secondary Hypertension Screening and Bridging Strategy

Young women with hypertension have a notable prevalence of primary aldosteronism, renovascular disease—particularly fibromuscular dysplasia—renal parenchymal disease, and, rarely, pheochromocytoma. This diagnostic evaluation must be completed prior to pregnancy. Pregnancy physiologically increases both renin and aldosterone, rendering the aldosterone-to-renin ratio unreliable. Undiagnosed pheochromocytoma in pregnancy also carries high maternal and fetal mortality risks.

For aldosterone-to-renin ratio testing, hypokalemia must first be corrected. Mineralocorticoid receptor antagonists and amiloride must be discontinued for at least four to six weeks. Whenever possible, ACE inhibitors and angiotensin receptor blockers should be withheld for at least two weeks, and diuretics for at least four weeks, as they elevate renin and lead to false-negative results. Beta-blockers, clonidine, and methyldopa should be discontinued for two weeks, as they suppress renin and cause false-positive results. Blood pressure control throughout the testing window should be maintained with home monitoring alongside sustained-release verapamil 120 to 240 mg daily, hydralazine 25 to 50 mg two to three times daily, or doxazosin 2 to 8 mg daily. If medication withdrawal is unsafe, the ratio should be interpreted with interfering medications taken into account: a suppressed renin level despite ACE inhibitor therapy remains highly suspicious. The same principles apply to the postpartum period when hypertension persists beyond 12 weeks.

Postpartum Blood Pressure Trajectory and Phenotypes

Postpartum phenotypes must be clearly categorized. Resolving gestational hypertension or preeclampsia normalizes within 6 to 12 weeks. Antihypertensive therapy should be tapered and discontinued once home blood pressure measurements consistently fall below 120–130/80 mmHg. Persistent hypertension extending beyond 12 weeks is reclassified as chronic hypertension, whether previously unrecognized or newly developed, and warrants an evaluation for secondary causes. Postpartum de novo preeclampsia is characterized by new-onset hypertension up to six weeks after delivery accompanied by findings such as headache, visual disturbances, epigastric pain, thrombocytopenia, or transaminase elevation. This clinical presentation warrants evaluation for hospitalization; in the presence of intractable neurological symptoms or features of severe disease, magnesium sulfate should be administered for seizure prophylaxis, and urgent antihypertensive therapy must be initiated when blood pressure is ≥160/110 mmHg.

Masked hypertension, defined by normal office readings but elevated home or ambulatory values, is common following preeclampsia and justifies 24-hour ambulatory monitoring at 6 to 12 months.

The recommended schedule entails a blood pressure check within 72 hours for women with severe features, a check at days 7 to 10 for all women with hypertensive disorders, and twice-daily home monitoring for at least two weeks. Values of 150/100 mmHg or higher should be treated, targeting a level below 140/90 mmHg. Values of 160/110 mmHg or higher should be treated urgently with oral immediate-release nifedipine 10 to 20 mg, intravenous labetalol (20 mg, escalating to 40 and 80 mg), or intravenous hydralazine 5 to 10 mg. Nonsteroidal anti-inflammatory drugs are acceptable analgesics for most women according to ACOG. More cautious guidelines advise avoiding them in women with renal impairment or difficult-to-control blood pressure.

Lactation-Compatible Dosing

Transfer of beta-blockers into breast milk varies by agent. In a case report of a woman treated with propranolol 40 mg daily throughout pregnancy, cord and maternal plasma concentrations were similar at delivery. Milk-to-plasma ratios remained below 1, and the estimated infant daily intake was calculated to be approximately 3 micrograms, leading the authors to conclude that avoidance of breastfeeding was unnecessary^[13]. This single-patient observation supports rather than proves compatibility.

The practical postpartum hierarchy is as follows: First-line: extended-release nifedipine, initiated at 30 to 60 mg once daily and titrated up to 120 mg daily; labetalol 100 to 200 mg two to three times daily, titrated according to blood pressure fluctuations and patient tolerability (noting that the increased clearance seen in pregnancy wanes postpartum and dosing frequency must be tailored to clinical response); or enalapril, initiated at 5 mg once daily and titrated to 10 to 20 mg twice daily. Enalapril is particularly well-suited for women with proteinuria, diabetes, or persistent hypertension. Second-line: amlodipine 5 to 10 mg once daily, metoprolol tartrate 25 to 100 mg twice daily, or captopril 12.5 to 50 mg two to three times daily. Agents to avoid: atenolol, due to its high transfer into breast milk and reported risk of neonatal bradycardia; and angiotensin receptor blockers, due to limited data unless no alternatives exist. Methyldopa should be discontinued within two days postpartum due to its association with postpartum depression. Loop diuretics may be used short-term in the setting of volume overload; however, high-dose diuretics can suppress lactation. Spironolactone at conventional doses is generally considered compatible with breastfeeding.

Safety Monitoring and Long-Term Follow-Up

Neonatal beta-blocker effects can be clinically significant. A term infant exposed to maternal metoprolol in utero developed persistent hypoglycemia within the first 12 hours of life despite glucose gel and formula supplementation, necessitating a four-day neonatal intensive care unit admission; the parents subsequently elected to discontinue breastfeeding^[14]. Beta-2 blockade impairs neonatal glycogenolysis and lipolysis. Therefore, infants exposed to beta-blockers, including labetalol, should undergo blood glucose screening during the first 24 hours. Nursing mothers should be counseled to report poor feeding, lethargy, or bradycardia, and reassured that such effects do not automatically necessitate discontinuation of breastfeeding.

For ACE inhibitors, maternal creatinine and potassium levels should be checked one to two weeks after initiation and following each dose escalation. Infant weight gain should be monitored, and caution is warranted in preterm infants or those with neonatal renal impairment. Nifedipine can cause headache, facial flushing, and edema, which may mimic preeclampsia and should not be overlooked.

Blood pressure should be reassessed at 6 to 12 weeks, urine protein-to-creatinine or albumin-to-creatinine ratio repeated, and the patient referred to nephrology if proteinuria persists for more than three months. Subsequent planning should include annual blood pressure measurements along with screening of lipids, glucose or HbA1c, and eGFR. A history of a hypertensive disorder of pregnancy should be documented as a risk-enhancing factor in cardiovascular risk calculators. Counseling should be provided regarding the high recurrence risk and the early initiation of aspirin in all future pregnancies.

Future Perspectives and Open Questions

Several fundamental questions remain unanswered. Foremost among them is the question of causality: Does preeclampsia directly induce vascular and renal damage, or does it merely unmask a preexisting predisposition? The answer will determine whether aggressive interventions in the postpartum period hold the potential to alter the lifelong trajectory or simply serve to identify women who warrant earlier conventional protection. Randomized controlled trials evaluating intensive blood pressure control, telemonitoring-supported self-management, and early initiation of cardioprotective agents in the postpartum period are ongoing. However, long-term evidence demonstrating a reduction in hard cardiovascular or renal events is not yet available.

The angiogenic axis is in the process of clinical translation. The sFlt-1/PlGF ratio has entered guidelines for the short-term rule-out of preeclampsia. Therapeutic apheresis for sFlt-1 removal, small interfering RNA (siRNA) targeting sFlt-1 expression, and recombinant PlGF are under investigation, with the latter two approaches largely in preclinical or early clinical stages. Whether postpartum angiogenic profiles predict chronic hypertension or eGFR decline remains unknown.

Nutritional prevention requires higher-quality studies. Signals observed for calcium and vitamin D in high-risk women are derived from small, heterogeneous trials lacking patient enrollment based on validated risk stratification. Adequately powered trials initiated preconceptionally and stratified by baseline intake are needed. Metabolic markers such as leptin currently carry only hypothesis-generating value due to wide confidence intervals (CIs) and a lack of demonstrated incremental benefit over clinical predictors. The growing use of incretin-based therapies for preconception weight reduction raises an emerging question regarding appropriate washout periods prior to conception.

Lactation pharmacology remains one of the most understudied areas of the literature in terms of high-level evidence from clinical trials. Much of the safety data for commonly used agents is derived from case reports, small pharmacokinetic series, and extrapolations from physicochemical properties. Meaningful infant exposure data are lacking for angiotensin receptor blockers, sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and newer agents. This reality forces many women to choose between optimal maternal cardiorenal protection and breastfeeding. Establishing systematic pharmacovigilance registries and enrolling lactating women in pharmacokinetic studies are long-overdue steps.

The most critical deficiency is organizational rather than scientific. Structured transition clinics bridging obstetrics, primary care, and cardiovascular medicine, standardized lifetime electronic health record coding of hypertensive pregnancies, and automated recall systems could translate a well-recognized risk marker into a measurable reduction in future events. Until such systems are established, the responsibility rests on every clinician encountering a woman with a history of a hypertensive disorder of pregnancy: to elicit this history, document it, and act on it.

References

1. Kuehn BM. Rising Prepregnancy Hypertension, Preeclampsia Disparities Raise Alarm. Circulation. 2021;143(7):753-754. doi:10.1161/CIRCULATIONAHA.120.053190. PubMed
2. Farina LA, Pool LR, Giase GM, Feinglass JM, Khan SS. Contemporary rates of pre-pregnancy hypertension and diabetes among a multi-ethnic sample of pregnant individuals in a diverse US state. Eur J Prev Cardiol. 2022;29(10):1460-1462. doi:10.1093/eurjpc/zwac073. PubMed
3. Robillard PY, Dekker G, Than NG, Bonsante F, Boukerrou M, Scioscia M, et al. Why only one-quarter of placental fetal growth restriction triggers preeclampsia? Clinical risk factors in 2060 cases in a 24-year cohort of 90,000 births. PLoS One. 2026;21(9):e0354687. doi:10.1371/journal.pone.0354687. PubMed
4. Dolstad H, Rifas-Shiman SL, Hivert MF, Aris IM, Faulkner J. Leptin levels in mid-pregnancy and risk of preeclampsia. Pregnancy Hypertens. 2026;45:101493. doi:10.1016/j.preghy.2026.101493. PubMed
5. Giorgione V. Pre-conception maternal cardiovascular health and obstetric complications due to uteroplacental insufficiency. BJOG. 2024;131(3):288-289. doi:10.1111/1471-0528.17666. PubMed
6. Gunabalasingam S, De Almeida Lima Slizys D, Quotah O, Magee L, White SL, Rigutto-Farebrother J, et al. Micronutrient supplementation interventions in preconception and pregnant women at increased risk of developing pre-eclampsia: a systematic review and meta-analysis. Eur J Clin Nutr. 2023;77(7):710-730. doi:10.1038/s41430-022-01232-0. PubMed
7. Ray JG, Abdulaziz KE, Berger H, DOH-NET (Diabetes, Obesity, and Hypertension in Pregnancy Research Network). Aspirin Use for Preeclampsia Prevention Among Women With Prepregnancy Diabetes, Obesity, and Hypertension. JAMA. 2022;327(4):388-390. doi:10.1001/jama.2021.22749. PubMed
8. Ghuman N, Rheiner J, Tendler BE, White WB. Hypertension in the postpartum woman: clinical update for the hypertension specialist. J Clin Hypertens (Greenwich). 2009;11(12):726-33. doi:10.1111/j.1751-7176.2009.00186.x. PubMed
9. Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010;341:c2207. doi:10.1136/bmj.c2207. PubMed
10. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA, et al. The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55(1):11-6. doi:10.1111/ajo.12253. PubMed
11. Faconti L, Abrams L, Jenner B, Shantsila E, Partridge S, Wilkinson IB. British and Irish Hypertension Society response to ‘RAAS inhibitors in pregnancy, breastfeeding and women of childbearing potential: a review of national and international clinical practice guidelines’. J Hum Hypertens. 2025;39(5):313-314. doi:10.1038/s41371-025-01004-w. PubMed
12. Shannon ME, Malecha SE, Cha AJ. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) and lactation: an update. J Hum Lact. 2000;16(2):152-5. doi:10.1177/089033440001600213. PubMed
13. Taylor EA, Turner P. Anti-hypertensive therapy with propranolol during pregnancy and lactation. Postgrad Med J. 1981;57(669):427-30. doi:10.1136/pgmj.57.669.427. PubMed
14. Ulloa JA, Sykes SR, Shihabuddin CD. Parental Advocacy in the NICU: A Unique Case of Infant Hypoglycemia Highlighting the Role of the Family in Improving Outcomes. Neonatal Netw. 2026;45(2):105-111. doi:10.1891/NN-2025-0038. PubMed

Share this article

LinkedIn X Facebook WhatsApp Copy Link